Study | Evaluated Outcomes | Results |
---|---|---|
Fu et al (Effectiveness of RAAS inhibitors vs CCBs) | Risk of initiation of renal replacement therapy (RRT), all-cause mortality, and cardiovascular events in older patients with advanced CKD in a 10-year cohort study | • Significantly lower risk of RRT initiation following new use of ACE inhibitors compared to new use of CCBs (adjusted HR, 0.79 [95%CI, 0.69–0.89]), but similar risks of mortality (adjusted HR, 0.97 [95%CI, 0.88–1.07]) and MACE (adjusted HR, 1.00 [95%CI, 0.88–1.15]). • The positive control cohort of patients with G3 CKD showed a similar reduction in the risk of RRT initiation (adjusted HR, 0.67 [95%CI, 0.56–0.80]) with ACE inhibitor therapy compared to CCBs. |
Lin et al (Systematic Review and Meta-Analysis comparing CCBs and RAAS inhibitors in patients with SAH and stage 3–5 CKD) | Changes in blood pressure, all-cause mortality, heart failure, cerebrovascular events, and renal outcomes. | • 21 studies with 9492 patients were analyzed and no significant differences were observed in any observed outcome. |
Zhao et al (Systematic Review and Meta-analysis) | 8 clinical trials with 25,647 patients were analyzed, examining the effect of CCBs on the incidence of CKD and all-cause mortality compared to ACE inhibitors and ARBs | • Decrease in blood pressure was similar for all pharmacological groups, with no significant difference in all-cause mortality, but finding a better nephroprotective effect for ACE inhibitors and ARBs compared to CCBs (IRR 0.96, 95%CI, 0.89–1.03). |